Analyst consensus rating
DiaMedica Therapeutics Analyst Consensus Rating
DMAC analyst consensus rating, coverage count and price target evidence.
Direct answer
DiaMedica Therapeutics's consensus rating is none.
4 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $15.50.
Forecast evidence checked August 7, 2026.
Verified data
- Current price
- $6.71
- Average price target
- $15.50
- High price target
- $25.00
- Low price target
- $11.00
- Target upside
- +131%
- Consensus rating
- none
- Analysts
- 4
- Evidence date
- August 7, 2026
- Valid through
- August 14, 2026